Market Cap 156.51B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 9.03
Forward PE 9.25
Profit Margin 12.42%
Debt to Equity Ratio 0.74
Volume 29,013,808
Avg Vol 36,545,449
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 27%
Beta 0.34
Analysts Sell
Price Target $28.92

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
simonds
simonds Sep. 18 at 1:57 PM
$PFE This beast will soar over $60/share by this years end!
0 · Reply
Bella838
Bella838 Sep. 18 at 1:01 PM
$PFE A fire was put down in their Andover facility. Nice work Andover FD….
0 · Reply
INEEDMONEY87
INEEDMONEY87 Sep. 18 at 12:56 PM
$PFE this is just an anti vaxer board now...... get a life, do you even trade? or just plan taxes and hate life so much you need an outlet?
1 · Reply
La_Parka3
La_Parka3 Sep. 18 at 11:43 AM
$MRNA $PFE They fear needles but rationalized it as antivax instead because admitting the truth will compromise their masculinity. 😆
0 · Reply
Diehard777
Diehard777 Sep. 18 at 5:27 AM
$PFE $SPY $MRNA (PFE) is much broader than its COVID business. Its portfolio spans oncology, inflammation & immunology, cardiovascular/metabolic disease, infectious diseases, rare diseases, and vaccines. Q1 2026 gives us a more encouraging signal: * Revenue excluding Comirnaty/Paxlovid: +7% operationally * Overall revenue: $14.5B * Eliquis: +13% * Oncology revenue: +9% * Padcev: +39% * Meanwhile, Comirnaty fell 59% and Paxlovid fell 62%. COVID is collapsing, yet the underlying Pfizer business is still growing. What you're paying for Management's 2026 guidance is: $59.5-62.5B revenue $2.80-$3.00 adjusted EPS At~$27.65, that means you're paying roughly: 9.2-9.9× 2026 adjusted earnings. That's cheap for a major pharmaceutical company if Pfizer can stabilize earnings around $3/share and eventually grow again
0 · Reply
Joker_brz
Joker_brz Sep. 18 at 3:22 AM
$PFE this will slowly melt towards $ 36.
2 · Reply
Samishere
Samishere Sep. 18 at 12:15 AM
0 · Reply
La_Parka3
La_Parka3 Sep. 17 at 11:48 PM
$MRNA $PFE Correction: "If we disagree politically, it's because you got the jab and 20 boosters, but you are still here alive and well and still able to call my anti-vaccine bullshit out when all this while me and my hommies thought you would be dead by now."
1 · Reply
Samishere
Samishere Sep. 17 at 11:40 PM
0 · Reply
goguryo2000
goguryo2000 Sep. 17 at 8:27 PM
$MRNA $PFE Yo man... Orange man and his friends fired dozen of stars in the military regarless of vaccine. Also kicking out illegals and shooting legals out of the country and their life. Not to mention messing with closest allies and Make America Disastrous Again. Obviously worse than the Biden era. Crazy inflation, and my salary is peer pressured by pumping gas and feeding family.
2 · Reply
Latest News on PFE
Pfizer price target raised to $30 from $28 at HSBC

2026-09-10T10:25:13.000Z - 8 days ago

Pfizer price target raised to $30 from $28 at HSBC


Trump administration to announce drug pricing deals

Aug 31, 2026, 12:09 PM EDT - 17 days ago

Trump administration to announce drug pricing deals

AMGN LLY TAK


Pfizer Stock (PFE) Is a Buy despite Declining Revenue

2026-08-24T12:18:00.000Z - 25 days ago

Pfizer Stock (PFE) Is a Buy despite Declining Revenue


Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Earnings Call Transcript: Q2 2026


Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Earnings release: Q2 2026


Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Slides: Q2 2026


Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Quarterly report: Q2 2026


Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 6 weeks ago

Pfizer Post Loss on Higher Revenue


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 2 months ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 2 months ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 2 months ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 2 months ago

Pfizer's experimental drug misses main goal of lung cancer trial


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 3 months ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 3 months ago

Pfizer Announces Chief Financial Officer Transition


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 3 months ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 3 months ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 3 months ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 3 months ago

Pfizer Press release: Study update


Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 3 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026


simonds
simonds Sep. 18 at 1:57 PM
$PFE This beast will soar over $60/share by this years end!
0 · Reply
Bella838
Bella838 Sep. 18 at 1:01 PM
$PFE A fire was put down in their Andover facility. Nice work Andover FD….
0 · Reply
INEEDMONEY87
INEEDMONEY87 Sep. 18 at 12:56 PM
$PFE this is just an anti vaxer board now...... get a life, do you even trade? or just plan taxes and hate life so much you need an outlet?
1 · Reply
La_Parka3
La_Parka3 Sep. 18 at 11:43 AM
$MRNA $PFE They fear needles but rationalized it as antivax instead because admitting the truth will compromise their masculinity. 😆
0 · Reply
Diehard777
Diehard777 Sep. 18 at 5:27 AM
$PFE $SPY $MRNA (PFE) is much broader than its COVID business. Its portfolio spans oncology, inflammation & immunology, cardiovascular/metabolic disease, infectious diseases, rare diseases, and vaccines. Q1 2026 gives us a more encouraging signal: * Revenue excluding Comirnaty/Paxlovid: +7% operationally * Overall revenue: $14.5B * Eliquis: +13% * Oncology revenue: +9% * Padcev: +39% * Meanwhile, Comirnaty fell 59% and Paxlovid fell 62%. COVID is collapsing, yet the underlying Pfizer business is still growing. What you're paying for Management's 2026 guidance is: $59.5-62.5B revenue $2.80-$3.00 adjusted EPS At~$27.65, that means you're paying roughly: 9.2-9.9× 2026 adjusted earnings. That's cheap for a major pharmaceutical company if Pfizer can stabilize earnings around $3/share and eventually grow again
0 · Reply
Joker_brz
Joker_brz Sep. 18 at 3:22 AM
$PFE this will slowly melt towards $ 36.
2 · Reply
Samishere
Samishere Sep. 18 at 12:15 AM
0 · Reply
La_Parka3
La_Parka3 Sep. 17 at 11:48 PM
$MRNA $PFE Correction: "If we disagree politically, it's because you got the jab and 20 boosters, but you are still here alive and well and still able to call my anti-vaccine bullshit out when all this while me and my hommies thought you would be dead by now."
1 · Reply
Samishere
Samishere Sep. 17 at 11:40 PM
0 · Reply
goguryo2000
goguryo2000 Sep. 17 at 8:27 PM
$MRNA $PFE Yo man... Orange man and his friends fired dozen of stars in the military regarless of vaccine. Also kicking out illegals and shooting legals out of the country and their life. Not to mention messing with closest allies and Make America Disastrous Again. Obviously worse than the Biden era. Crazy inflation, and my salary is peer pressured by pumping gas and feeding family.
2 · Reply
goguryo2000
goguryo2000 Sep. 17 at 8:17 PM
$PFE I haven't checked this for a while. Why is this under 29?? I was happy to see 29 last time i checked. Lol. Come on, back to 29 and go beyond 30 already!!!
1 · Reply
KTGAMBLESTOCKS
KTGAMBLESTOCKS Sep. 17 at 7:52 PM
$IBRX $MRNA $PFE $UNH Let us see what this does.
0 · Reply
taxplanr
taxplanr Sep. 17 at 7:29 PM
Breaking another new study shows the lipid nano particle in mRNA induces cancer $MRNA $MRK $BNTX $PFE https://www.instagram.com/reel/DdZJH24Bfcf/?stkn=MWh6MjdreXA5czlvbw==
0 · Reply
Sak12345
Sak12345 Sep. 17 at 6:50 PM
$PFE TOKENIZED STOCKS https://defichain.com/
0 · Reply
TraderDaKing
TraderDaKing Sep. 17 at 3:51 PM
$PFE $JNJ $AMC $SPCX Something is going on with ELTP. Elite is a New Jersey based company. Buy now people.
0 · Reply
GoforProMIS
GoforProMIS Sep. 17 at 2:16 PM
$PMN on Monday 21st September „ProMIS Neurosciences and NASDAQ mark World Alzheimer’s Day at the NASDAQ Tower“ The focus of PMN is not merely a data release, but an official event taking center stage in the financial world! Interesting isn’t it? $BIIB $LLY $PFE
0 · Reply
zustrelaax
zustrelaax Sep. 17 at 2:08 PM
$PFE purposefully putting it down, looks like news around the corner
0 · Reply
Makingmillions192
Makingmillions192 Sep. 17 at 1:14 PM
$LEXX “In parallel, we have made significant progress on the business development front and as a result, we expect to spend less of our own resources to fund R&D efforts in 2027. Our intent is to continue to pursue additional business development relationships and effectively transfer certain R&D costs to our partners.” Lexaria will have progress updates on its ongoing 2026 R&D programs soon, and will also have guidance towards our 2027 R&D programs now that the financing activities are complete and budgets can be assembled.“ $LLY $NVO $PFE $VIK https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-updates-financial-position-1222758
0 · Reply
Samishere
Samishere Sep. 17 at 12:55 PM
0 · Reply
La_Parka3
La_Parka3 Sep. 17 at 10:17 AM
$MRNA $PFE The shorts are in huge trouble. Stéphane Bancel and Albert Bourla have reportedly complained to Bill Gates, the Rothschilds, the Illuminati, the Bilderberg Group, the Freemasons, the World Economic Forum, the Vatican Secret Archives, the Deep State, the New World Order, and apparently the Lizard People about two straight years of bullying by short sellers trying to derail the agenda. Now the entire shadow government, plus three reptilian councils and one undisclosed moon base, is allegedly coordinating a short squeeze to teach them a lesson. 😂
0 · Reply
The5ersFutures
The5ersFutures Sep. 17 at 7:32 AM
$PFE raised the top line. COVID still collapsed. Comirnaty -34% operational. Paxlovid -95%. Non-COVID +5%. New and acquired products +18%. Guidance now $60.5B-$62.5B after a $500M midpoint raise. COVID outlook cut $1B to about $4B. Innovent deal: $650M upfront, up to $9.85B milestones, $0.10 EPS hit in Q3. Seagen mix is uneven. Padcev +23%. Other inherited oncology brands fell. SigVie-002 miss triggered $3.8B IPR&D impairment. Total write-downs $4.3B. Reported EPS $(0.04). Savings target is $9.7B through 2029. Patent replacement is the real test. $PFE $MRK $LLY $ABBV $BMY #Pfizer #Pharma #Oncology #PatentCliff #Earnings
0 · Reply
EntryPointInvestor
EntryPointInvestor Sep. 17 at 4:15 AM
$PFE Levels to watch on Pfizer right now: resistance sits at $28.07 and support is down at $26.5, with the stock currently trading at $27.48. The chart carries a cautiously bullish lean at the moment. 🤔 It's in an uptrend, and that context shapes how these levels matter. In an uptrend, dips tend to get bought and breakouts tend to carry more conviction. A sustained push above $28.07 would strengthen the current structure and keep the bullish case intact. On the other side, a drop below $26.5 would start to weaken things and deserve close attention. Neither of those levels has been tested just yet, so for now the chart's tilting in a constructive direction. Worth keeping an eye on if you follow this one. Curious what the actual entry points look like? We have it all laid out just not in this small post. Not investment advice.
0 · Reply